Clinical Report: Impact of ABCB1 and CYP2C19 Genetic Variants on MACE
Overview
This study evaluates the influence of ABCB1 and CYP2C19 genetic variants on major adverse cardiovascular events (MACE) in clopidogrel-treated patients with acute coronary syndrome (ACS). The findings show no significant association between ABCB1 variants and MACE, while CYP2C19*2 showed a weak trend towards increased risk.
Background
Understanding genetic factors influencing clopidogrel response is crucial for optimizing treatment in patients with ACS. CYP2C19 polymorphisms are well-established as significant determinants of clopidogrel efficacy. The role of ABCB1 variants requires further investigation.
Data Highlights
No significant correlation was found between ABCB1 alleles and MACE outcomes (p-value > 0.05). CYP2C19*2 showed a weak trend of increased MACE risk (RR = 1.41; 95% CI: 0.95–2.10; p-value = 0.08).
Key Findings
The study included 174 patients with ACS treated with clopidogrel.
Minor allele frequencies for ABCB1 variants were 48.85% (rs1045642), 50% (rs2032582), and 51.44% (rs1128503).
ABCB1 variants showed no significant correlation with MACE outcomes.
CYP2C19*2 was associated with a weak trend of increased MACE risk.
Age was the only factor showing a non-significant trend towards higher risk in multivariable analysis.
Clinical Implications
The findings indicate that ABCB1 genotyping may have limited utility in predicting clopidogrel response in ACS patients. CYP2C19 genotyping remains a focus for optimizing antiplatelet therapy.
Conclusion
This study found no significant association between ABCB1 variants and MACE, while CYP2C19*2 was associated with a weak trend of increased risk.
by Lubna Q. Khasawneh, Mais N. Alqasrawi, Zeina N. Al-Mahayri, Lilas Dabaghie, Sahar M. Altoum, Gohar Jamil, Salahdein Aburuz, Dana Hamza, Lizy George, Faiz Al-Bakshy, Kaes Al-Anee, Khuzama AlAhamad, Fatma Al-Maskari, Husam Ouda, Juma AlKaabi, George P. Patrinos, Bassam R. Ali
Data presented at the American College of Cardiology 75th Annual Scientific Session linked pregnancy-associated SCAD to more severe presentation and higher in-hospital major adverse cardiovascular events.
